Ustekinumab Injection bulk supplier for pharma manufacturers

Ustekinumab Injection Suppliers & Bulk Manufacturers

Available Forms: SQ and IV injection

Available Strengths: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Reference Brands: Stelara(US)

Ustekinumab inhibits interleukins IL-12 and IL-23, key cytokines involved in inflammatory and immune responses. It reduces inflammation, alleviates symptoms of psoriasis, psoriatic arthritis, and Crohn’s disease, and improves quality of life. Benefits include targeted action, long-term disease control, and a favorable safety profile in autoimmune therapy.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Ustekinumab injection, marketed as Stelara, is approved in the US by the FDA and in the EU via EMA for Crohn’s disease, psoriatic arthritis, and psoriasis. Regulatory approval requires comprehensive dossiers including clinical trial data, manufacturing details, safety, efficacy, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and quality data, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market entry strategies, visit PharmaTradz. Ensuring thorough regional compliance is essential for the safe, effective, and timely approval of ustekinumab injectable products worldwide, supporting optimal patient outcomes in autoimmune disease management.

Ustekinumab Injection — third party manufacturing & bulk supply

Ustekinumab Injection is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ustekinumab Injection is supplied as SQ and IV injection — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ustekinumab Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ustekinumab Injection →

Back to Listing

Frequently Asked Questions

Ustekinumab Injection is listed as SQ and IV injection in SQ:: 45 mg, 90 mg; IV: 130 mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ustekinumab Injection is referenced against Stelara(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.